High doses of bifendate elevate serum and hepatic triglyceride levels in rabbits and mice: Animal models of acute hypertriglyceridemia

Acta Pharmacologica Sinica

Volumn 27, Issue 6, 2006, Pages 673-678

  Pan, Si Yuan ^a   Yang, Rong ^a   Han, Yi Fan ^b   Dong, Hang ^a   Feng, Xu Dong ^a   Li, Na ^a   Geng, Wei ^a   Ko, Kam Ming ^b  

^a BEIJING UNIVERSITY OF CHINESE MEDICINE   (China)

^b HONG KONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Hong Kong)

Author keywords

Acute hypertriglyceridemia; Bifendate; Fenofibrate; Inositol nicotinate; Total cholesterol; Triglycerides

Indexed keywords

ANTILIPEMIC AGENT; APOLIPOPROTEIN A1; APOLIPOPROTEIN B; BIFENDATE; BILE SALT; BIPHENYLDICARBOXYLATE; FENOFIBRATE; FIBRIC ACID DERIVATIVE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INOSITOL NICOTINATE; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NATURAL PRODUCT; SCHIZANDRIN B; SCHIZANDRIN C; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ACUTE DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DRUG EFFECT; DRUG MEGADOSE; HEPATITIS; HYPERLIPIDEMIA; HYPERTRIGLYCERIDEMIA; LIVER; MALE; MOUSE; NONHUMAN; RABBIT; TOXIC HEPATITIS; TRIACYLGLYCEROL BLOOD LEVEL;

ANIMALS; ANTILIPEMIC AGENTS; APOLIPOPROTEIN A-I; APOLIPOPROTEINS B; BIPHENYL COMPOUNDS; CHOLESTEROL; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; HYPERTRIGLYCERIDEMIA; LIVER; MALE; MICE; MICE, INBRED ICR; PROCETOFEN; RABBITS; TRIGLYCERIDES;

EID: 33745414014     PISSN: 16714083     EISSN: 17457254     Source Type: Journal    
DOI: 10.1111/j.1745-7254.2006.00332.x     Document Type: Article

References (28)

1. Chen ZM Peto R Collins R MacMahon S Lu J Li WC. Continuous positive relationship between serum cholesterol and coronary heart disease in a population with low mean cholesterol. Br Med J 1991 303 : 276 82.
2. Wakugami K Iseki K Kimura Y Okumura K Ikemiya Y Muratani H, et al. Relationship between serum cholesterol and the risk of acute myocardial infarction in a screened cohort in Okinawa, Japan. Jpn Circ J 1998 62 : 7 14.
3. Khoo KL Tan H Liew YM Deslypere JP Janus E. Lipids and coronary heart disease in Asia. Atherosclerosis 2003 169 : 1 10.
4. Breslow JL. Mouse models of atherosclerosis. Science 1996 272 : 685 8.
5. Breslow JL. Transgenic mouse models of lipoprotein metabolism and atherosclerosis. Proc Natl Acad Sci USA 1993 90 : 8314 8.
6. Delawi D Meijssen S Castro CM. Intra-individual variations of fasting plasma lipids, apolipoproteins and postprandial lipemia in familial combined hyperlipidemia compared to controls. Clin Chim Acta 2003 328 : 139 45.
7. Ueno T Tremblay J Kunes J Zicha J Dobesova Z Pausova Z, et al. Rat model of familial combined hyperlipidemia as a result of comparative mapping. Physiol Genomics 2004 17 : 38 47.
8. Vrana A Kazdova L. The hereditary hypertriglyceridemic nonobese rat: an experimental model of human hypertriglyceridemia. Transplant Proc 1990 22 : 2579.
9. Pan SY Han YF Carlier PR Pang YP Mak DHF Lam BYH, et al. Schisandrin B protects against tacrine- and bis(7)-tacrine-induced hepatotoxicity and enhances cognitive function in mice. Planta Med 2002 68 : 217 20.
10. Pan SY. New use of schisandrin. Chin Bull Inve Patent 2000 16 : 11.
11. Liu GT. From the study of Fructus Schizandrae to the discovery of biphenyl dimethyl-dicarboxylate. Acta Pharm Sin 1983 18 : 714 20.
12. Liu GT Wei HL Song ZY. Further studies on the protective action of biphenyl dimethyl-dicarboxylate (BDD) against experimental liver injury in mice. Acta Pharm Sin 1982 17 : 101 5.
13. Rekhter MD. How to evaluate plaque vulnerability in animal models of atherosclerosis Cardiovas Res 2002 54 : 36 41.
14. Joniken MP Clarkson JB Pritchard RW. Recent advances in molecular pathology: animal models in atherosclerosis. Exp Mol Pathol 1985 42 : 1 28.
15. Klein CJ Stanek GS Wiles CE. Overfeeding macronutrients to critically ill adults: metabolic complications. J Am Diet Assoc 1998 98 : 795 806.
16. Eaton S Record CO Bartlett K. Multiple biochemical effects in the pathogenesis of alcoholic fatty liver. Eur J Clin Invest 1997 27 : 719 22.
17. Hokanson JE Austin MA. Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: a meta-analysis of population-based prospective studies. J Cardiovasc Risk 1996 3 : 213 9.
18. Fromenty B Pessayre D. Impaired mitochondrial function in microvesicular steatosis. Effects of drugs, ethanol, hormones and cytokines. J Hepatol 1997 26 ( Suppl 2 43 53.
19. Guerin M Le Goff W Lassel TS Van Tol A Steiner G Chapman MJ. Proatherogenic role of elevated CE transfer from HDL to VLDL1 and dense LDL in type 2 diabetes: impact of the degree of triglyceridemia. Arterioscler Thromb Vasc Biol 2001 21 : 282 8.
20. Wang XL Yi MG Liu ZM Sung CY. The physiological dispositions of biphenyl dimethyl-dicarboxylate (BDD). Acta Pharm Sin 1983 18 : 892 9.
21. Ikewaki K Tohyama J Nakata Y Wakikawa T Kido T Mochizuki S. Fenofibrate effectively reduces remnants, and small dense LDL, and increases HDL particle number in hyper-triglyceridemic men-a nuclear magnetic resonance study. J Atheroscler Thromb 2004 11 : 278 85.
22. Saklamaz A Comlekci A Temiz A Caliskan S Ceylan C Alacacioglu A, et al. The beneficial effects of lipid-lowering drugs beyond lipid-lowering effects: a comparative study with pravastatin, atorvastatin, and fenofibrate in patients with type IIa and type IIb hyperlipidemia. Metabolism 2005 54 : 677 81.
23. Tsimihodimos V Miltiadous G Daskalopoulou SS Mikhailidis DP Elisaf MS. Fenofibrate: metabolic and pleiotropic effects. Cur Vasc Pharmacol 2005 3 : 87 98.
24. Jeong S Han M Lee H Kim M Kim J Nicol CJ, et al. Effects of fenofibrate on high-fat diet-induced body weight gain and adiposity in female C57BL/6J mice. Metabolism 2004 53 : 1284 9.
25. Wink J Giacoppe G King J. Effect of very-low-dose niacin on high-density lipoprotein in patients undergoing long-term statin therapy. Am Heart J 2002 143 : 514 8.
26. Grundy SM Vega GL McGovern ME Tulloch BR Kendall DM Fitz-Patrick D, et al. Efficacy, safety, and tolerability of once-daily niacin for the treatment of dyslipidemia associated with type 2 diabetes: results of the assessment of diabetes control and evaluation of the efficacy of niaspan trial. Arch Intern Med 2002 162 : 1568 76.
27. Sunderland GT Belch JJ Sturrock RD Forbes CD McKay AJ. A double blind randomised placebo controlled trial of hexopal in primary Raynaud's disease. Clin Rheumatol 1988 7 : 6 49.
28. Elam MB Hunninghake DB Davis KB Garg R Johnson C Egan D, et al. Effect of niacin on lipid and lipoprotein levels and glycemic control in patients with diabetes and peripheral arterial disease: the ADMIT Study: a randomized trial. Arterial Disease Multiple Intervention Trial. JAMA 2000 284 : 1263 70.